CAS Number: 9039-53-6
Standard: In-house

Urokinase is a therapeutic enzyme originally isolated from healthy human urine or produced through human kidney cell culture. As a clinically important thrombolytic agent , it plays a vital role in dissolving dangerous blood clots and restoring normal circulation. Its strong fibrinolytic activity has made it a cornerstone in emergency medicine and cardiovascular care.

What is urokinase?

Urokinase is a serine protease enzyme that activates the body's natural fibrinolytic system. It converts plasminogen into plasmin , the primary enzyme responsible for breaking down fibrin-the framework structural of blood clots. By accelerating this natural process, urokinase helps clear obstructed blood vessels and prevents tissue damage caused by impaired blood flow.

Mechanism of Action

• Binds to plasminogen at the clot site
• Converts plasminogen → plasmin
• Plasmin breaks down fibrin strands , dissolving blood clots
• Restores circulation , reducing risk of tissue death and organ damage

This targeted breakdown of fibrin makes urokinase particularly valuable in acute and life-threatening thrombotic conditions.

Applications of Urokinase

Safety Profile and Administration

Urokinase is FDA-approved and well-established in clinical practice. It is generally administered intravenously , which allows for controlled dosing and rapid therapeutic response.

• ▸ High thrombolytic effectiveness
• ▸ Predictable action profile
• ▸ Convenient IV administration
• ▸Suitable for emergency protocols
• ▸ Helps reduce hospitalization time

Conclusion

Urokinase (CAS 9039-53-6) is a powerful thrombolytic enzyme with an essential role in treating serious clot-related medical conditions. By accelerating the natural breakdown of fibrin clots, it helps prevent organ damage, improves patient outcomes, and saves lives.